FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileBCAL Diagnostics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
BDX.AX
BCAL Diagnostics Limited Stock AnalysisComprehensive stock analysis for BCAL Diagnostics Limited (BDX.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBDX.AX
BDX.AX
BCAL Diagnostics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
BDX.AX
  1. Home
  2. Stocks
  3. BCAL Diagnostics Limited

BCAL Diagnostics Limited

🇦🇺BDX.AX•ASX

BCAL Diagnostics Limited

🇦🇺BDX.AX•ASX

Your view on BDX.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About BCAL Diagnostics Limited

Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Anne-Louise Arnett
Headquarters
50 Clarence Street, Sydney, NSW, AU
Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Anne-Louise Arnett
Headquarters
50 Clarence Street, Sydney, NSW, AU
Description

BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring.

This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for BCAL Diagnostics Limited. Starting points for BCAL Diagnostics Limited: EPS -AUD 0.02, beta 0.82 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for BCAL Diagnostics Limited. BCAL Diagnostics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for BCAL Diagnostics Limited. Trailing twelve-month EPS for BCAL Diagnostics Limited stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for BCAL Diagnostics Limited. BCAL Diagnostics Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold BDX.AX20 companies
Compare BDX.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
AGN.AXArgenica Therapeutics LtdHealthcareBiotechnology—
AT1.AXAtomo Diagnostics LimitedHealthcareMedical - Devices—
EMD.AXEmyria LimitedHealthcareMedical - Healthcare Information Services—
EYE.AXNova Eye Medical LimitedHealthcareMedical - Devices—
HMD.AXHeraMED LimitedHealthcareMedical - Devices—
IDT.AXIDT Australia LimitedHealthcareDrug Manufacturers - Specialty & Generic—
IIQ.AXINOVIQ LtdHealthcareMedical - Diagnostics & Research—
MAP.AXMicroba Life Sciences LimitedHealthcareMedical - Diagnostics & Research—
More Medical - Diagnostics & Research companies
TickerTypeCompanySectorExchangeMkt cap
ILMNIllumina, Inc.HealthcareNASDAQ$31.8B
IMDXInsight Molecular Diagnostics Inc.HealthcareNASDAQ$52.1M
IME.AXImExHS LimitedHealthcareASX—
IMMVFImmunovia AB (publ)HealthcareOTC$6.1M
IQVIQVIA Holdings Inc.HealthcareNYSE$42.5B
ISPCiSpecimen Inc.HealthcareNASDAQ$1.3M
IVROInVitro InternationalHealthcareOTC$1.8M
IZO.CNIzotropic CorporationHealthcareCNQ$20.6M
IZOZFIzotropic CorporationHealthcareOTC$11.9M
JMPHFLeveljump Healthcare Corp.HealthcareOTC$15.2M
LDDDLongduoduo Company LimitedHealthcareOTC$15.3M
LHLabcorp Holdings Inc.HealthcareNYSE$30.1B
Open Comparable Analysis
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of BCAL Diagnostics Limited.

BDX.AX AnalysisWeak
Past
1
Growth
1
Health
1
Profit
1
Value
1